Zobrazeno 101 - 110
of 21 697
pro vyhledávání: ''
Autor:
Xiaoyong Huang, Zhiqiang Wu, Wenbo Guo, Zhiyong Liu, Tengfei Li, Xu Bo, Weiguang Yu, Song Chen, Yanqing Wu, Pengfei Wang
Publikováno v:
BMC Cancer, Vol 21, Iss 1, Pp 1-13 (2021)
BMC Cancer
BMC Cancer
Background Not all patients with unresectable hepatocellular carcinoma (uHCC) benefit from treatment with immune checkpoint inhibitors and molecular-targeted agents. The aim of this retrospective study was to assess the efficacy and safety of pembrol
Autor:
Yansong Liu, Xinzhao Wang, Chao Li, Xiaoli Bian, Zhaoyun Liu, Xiang Song, Wei Zhao, Zhiyong Yu
Publikováno v:
Cancer Medicine
Cancer Medicine, Vol 10, Iss 23, Pp 8352-8364 (2021)
Cancer Medicine, Vol 10, Iss 23, Pp 8352-8364 (2021)
The previous studies had demonstrated the promising effectiveness and acceptable safety of pyrotinib in patients with HER2‐positive metastatic breast cancer. We aimed to investigate the real‐world data of pyrotinib in complex clinical practice an
Autor:
Minghua Ge, Yan-Yan Liu, Zhengdong Li, Liangfang Shen, Qingyuan Zhang, Yi Luo, Jifeng Feng, Ye Guo, W. Chen, Kun-Yu Yang, Xiaohui He, Kai Xue, Yan Sun, T. Lin, Xiao-Dong Zhu, Xiao Ming Huang, XinYing Chang, Chunmei Bai, Yan Zeng, Lin Wang
Publikováno v:
European Journal of Cancer. 156:35-45
Background The EXTREME regimen (chemotherapy [CT; cisplatin/carboplatin and 5-fluorouracil]) plus cetuximab is a standard-of-care first-line (1L) treatment for patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (R/
Autor:
Frederic Peyrade, Graham P. Collins, Yihua Lee, Jutta K. Neuenburg, Michael Wang, Robert T. Chen, Geoffrey Chong, Karl Eckert, Constantine S. Tam, Radhakrishnan Ramchandren, Lionel Karlin, Ka Lung Wu, Mark Bishton, Paul Eliadis, Wojciech Jurczak
Publikováno v:
Journal of Hematology & Oncology, Vol 14, Iss 1, Pp 1-8 (2021)
Journal of Hematology & Oncology
Journal of Hematology & Oncology
Ibrutinib plus venetoclax, given with an ibrutinib lead-in, has shown encouraging clinical activity in early phase studies in mantle cell lymphoma (MCL). The ongoing phase 3 SYMPATICO study evaluates the safety and efficacy of concurrently administer
Autor:
Hagop M. Kantarjian, Nicholas J. Short
Publikováno v:
J Clin Oncol
Autor:
Frederik Marmé, Helmut Forstbauer, Jens Huober, Gbg, Bruno Valentin Sinn, Michael Untch, Jenny Furlanetto, Christian Jackisch, Jens-Uwe Blohmer, Hans-Joachim Lück, Knut Engels, Ago-B, Grischa Wachsmann, Ekkehart Ladda, Nicole Burchardi, Elmar Stickeler, Sabine Schmatloch, Sibylle Loibl, Mattea Reinisch, Theresa Link, Volker Möbus, Carsten Denkert, Eva-Maria Grischke, Peter Klare, Marcus Schmidt, Christine Solbach, Andreas Schneeweiss, Julia Rey, Wolfgang Janni
Publikováno v:
European Journal of Cancer. 156:138-148
Background The GAIN-2 trial was designed to identify a superior intense dose-dense (idd) strategy for high-risk patients with early breast cancer. Here, we report an interim analysis, at which the predefined futility boundary was crossed. Patients an
Autor:
M. Faehling, Frank Heinzelmann, Rainer Sätzler, Susanne Martina Eschmann, Jörn Sträter, Sabine Fallscheer, Sebastian Kramberg
Publikováno v:
European Journal of Cancer. 156:175-186
Background Recent phase II–III trials of immuno(chemo)therapy before resection in locally advanced resectable non-small cell lung cancer (NSCLC) report high rates of pathological response and promising survival. However, primarily, patients who did
Autor:
Jean El Cheikh, Iman Abou Dalle, Jeries Kort, Farouk Al Chami, Maya Charafeddine, Haidar El Darsa, Rola El Sayed, Ali Ibrahim, Ali Bazarbachi
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 21:711-719
Background Intensified immunochemotherapy with rituximab, doxorubicin, cyclophosphamide, vindesine, bleomycin, and prednisone (R-ACVBP) improves outcomes in younger adults with diffuse large B-cell lymphomas (DLBCL) compared with R-CHOP. Due to vinde
Autor:
Haiyan Xu, Lu Yang, Shucai Zhang, Shuyang Zhang, Yaning Yang, Yan Wang, Guangjian Yang, Xin Ai, Li Ma
Publikováno v:
Cancer Medicine
Cancer Medicine, Vol 10, Iss 23, Pp 8328-8337 (2021)
Cancer Medicine, Vol 10, Iss 23, Pp 8328-8337 (2021)
Background There was no standard treatment for patients who acquired resistance to osimertinib mediated by epidermal growth factor receptor (EGFR) T790M‐cis‐C797S. The aim of this study was to investigate the association between different therape
Autor:
Wenqi Jiang, Li-Qin Ping, Qingqing Cai, Bing Bai, Xiaoxiao Wang, Jibin Li, Qixiang Rong, Jia-Ying Mao, Yan-Xia He, Haixia He, Cheng Huang, Yan Gao, Zhi Ming Li, He Huang, Huiqiang Huang
Publikováno v:
Cancer Medicine
Cancer Medicine, Vol 10, Iss 21, Pp 7650-7664 (2021)
Cancer Medicine, Vol 10, Iss 21, Pp 7650-7664 (2021)
Purpose Some studies have indicated that using 500 mg/m2 rituximab combined with CHOP‐14 may be beneficial for elderly men but not women with diffuse large B‐cell lymphoma (DLBCL). The purpose of this study was to investigate the potential benefi